Aikido pharma inc. (SPEX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities
Net loss

-11,367

-4,183

346

1,818

2,064

1,727

-4,761

-2,411

-3,873

-3,306

-6,223

-7,128

-7,346

-6,476

-6,918

-9,198

-47,428

-51,465

-52,977

-55,395

-26,655

-30,532

-28,856

-32,992

-22,231

-17,965

-15,694

-7,122

-6,719

-3,857

0

0

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of patent portfolio

-

-

-

-

-

1,405

1,373

1,373

1,373

1,373

1,564

1,754

1,942

2,135

0

0

0

-

-

-

9,825

9,831

7,487

5,145

2,695

267

0

0

0

-

-

-

-

-

-

-

-

Change in fair value of investment

-3,190

1,406

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash registration rights penalty

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

654

654

654

700

0

0

0

0

-

-

-

-

-

-

-

-

Change in fair value of warrant liabilities

-

82

261

349

499

740

699

1,671

190

-120

-57

-100

593

2,257

0

0

0

-

-

-

88

48

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Research and development-acquired license, expensed

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on settlement of obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-845

0

0

0

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

64

64

63

66

0

0

0

Fair value adjustment of warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Recovery of bad debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Stock-based compensation

-

329

335

149

138

320

324

298

207

23

222

274

435

562

501

536

415

371

945

2,422

9,367

12,676

0

0

0

-

-

-

57

56

0

0

0

-

-

-

-

Fair value adjustments for warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Depreciation expense

-

-

-

-

-

38

39

20

3

3

4

2

4

3

0

0

0

-

-

-

-

-

-

-

-

24

0

0

0

-

-

-

-

-

-

-

-

Realized loss on marketable securities

-143

-172

-169

-223

-374

-400

-386

-474

-334

-328

-398

-167

-122

-95

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized loss (gain) on marketable securities

-838

145

29

38

89

-117

-36

86

110

240

81

-135

-183

-243

0

0

0

-

-

-

3

-54

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Other receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

0

0

0

-

-

-

-

262

0

0

0

Prepaid expenses and other assets

-5

-7

-24

-40

-58

38

34

51

83

15

-17

-4

-147

-195

39

26

221

223

-214

-142

-124

-44

9

23

16

-14

-20

-22

8

236

1,010

795

600

289

0

0

0

Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Accounts payable and accrued expenses

48

-64

187

24

-46

74

20

103

-9

-67

-16

-157

-180

-261

-377

-251

-319

-344

296

-260

335

458

-112

607

173

-158

173

214

101

193

-26

-84

-11

-366

0

0

0

Accrued salaries and benefits

-210

-50

16

13

23

37

309

510

286

249

-265

8

228

-199

319

-191

-523

316

176

224

557

96

-246

-244

-208

-52

0

0

0

-

-

-

-

-

-

-

-

Payable to DatChat

-73

107

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-1,216

-1,247

-1,247

3,261

3,497

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-3

-3

-24

-34

-33

0

0

0

Accrued lease liabilities

-

-

-

-

-

-48

-94

-140

-187

-179

-180

-177

-175

-180

0

0

0

-

-

-

537

580

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of patent portfolio

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,000

0

0

0

-

-

-

-

-

-

-

-

Net cash used in operating activities

-3,569

-3,017

-2,669

-2,593

-2,549

-2,729

-3,014

-3,206

-3,503

-3,272

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities
Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Deferred compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-305

0

0

0

Net cash used in activities of continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,352

-5,037

-3,926

-3,684

-3,648

0

0

0

-

-

0

0

Net cash provided by (used in) activities of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

86

-102

-100

-14

-167

0

0

0

-

-

-

-

Net cash (used in) provided by operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-324

-4,799

-4,620

-8,463

-8,723

-9,331

-9,516

-6,394

-6,573

-5,737

-5,266

-5,140

-4,026

-3,699

-3,815

-3,571

-3,571

-3,952

-4,359

0

0

0

Purchase of marketable securities

25,994

8,461

7,621

9,187

11,785

14,280

14,301

15,811

13,493

12,274

13,611

14,352

18,700

18,035

19,927

14,413

7,681

7,994

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sale of marketable securities

10,127

10,277

9,953

12,820

15,819

15,061

15,204

13,708

12,778

14,213

15,528

16,803

14,781

15,065

13,737

9,524

9,035

8,121

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of investments at fair value

-

200

0

0

0

-

-

-

-

675

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of research and development licenses

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

-

-

-

-

-

36

0

0

0

-

-

-

-

4

5

5

4

2

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of accrued patent costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by activities of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net cash (used in) provided by investing activities

-17,238

1,256

1,563

2,192

2,927

-151

190

-2,144

-1,415

1,264

0

0

0

-

-

-

0

-

-

-

643

-1,000

-1,028

-342

-342

658

685

3

3

2

0

0

0

-

-

-

-

Cash flows from financing activities
Proceeds from issuance common stock, common warrants and prefunded warrants, net of offering cost

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

0

0

0

Proceeds from issuance common stock, net of offering cost

0

-

-

-

-

2,700

2,700

4,795

4,795

2,095

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,544

2,638

4,034

0

0

0

Proceeds from issuance of common stock and warrants in July Financing, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

4,184

4,184

4,210

310

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net cash provided by financing activities

0

-

-

-

-

2,700

2,700

4,795

4,771

2,071

0

0

0

-

-

-

-

-

-

-

-

8,196

10,431

11,041

7,135

3,235

3,346

2,844

2,333

3,400

0

0

0

-

-

-

-

Issuance cost of common stock and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net cash (used in) provided byfinancing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,220

3,700

0

0

0

Net increase in cash and cash equivalents

-189

74

204

386

378

-180

-124

-555

-147

63

-70

341

-284

-8

146

305

383

-663

-5,393

-7,059

-4,392

-2,320

3,009

4,126

1,056

-1,373

-1,108

-1,178

-1,361

-413

0

0

0

-

-

-

-

Cash paid for interest and taxes

-

-

-

-

-

-

-

-

-

195

195

0

0

0

0

0

0

-

-

-

0

0

0

0

0

-

-

-

-

-

0

0

0

-

-

-

-

Cash paid for interest and taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Non-cash investing and financing activities
Offering cost included in accrued expenses

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Retirement of treasury stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

201

201

201

201

0

0

0

0

-

-

-

-

-

-

-

-

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of Series C Convertible Preferred Stock in connection with exchange of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Issuance of Series C Convertible Preferred Stock in connection with exchange of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-